{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:07:22Z","timestamp":1789762042787,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.111030","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:29:53Z","timestamp":1771417793000},"page":"693-699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Review of radiopharmaceutical therapy in prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5059-2209","authenticated-orcid":false,"given":"Sean R.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuni","family":"Dewaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachery R.","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Viglianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2026.111030_bib0001","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111030_bib0002","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111030_bib0003","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res"},{"issue":"20 Pt 2","key":"10.1016\/j.urolonc.2026.111030_bib0004","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111030_bib0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-023-07147-z","article-title":"Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials","volume":"204","author":"Rugo","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2026.111030_bib0006","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e21211","article-title":"Radium-223 following front-line chemotherapy for patients with non-small cell lung cancer and bone metastases","volume":"36","author":"Taber","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2026.111030_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4593","article-title":"A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL\/Alliance A031801)","volume":"39","author":"McKay","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111030_bib0008","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111030_bib0009","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10276","key":"10.1016\/j.urolonc.2026.111030_bib0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111030_bib0011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10459","key":"10.1016\/j.urolonc.2026.111030_bib0012","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111030_bib0013","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","article-title":"Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial","volume":"26","author":"Fizazi","year":"2025","journal-title":"Lancet Oncol"},{"issue":"0","key":"10.1016\/j.urolonc.2026.111030_bib0014","article-title":"Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"0","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111030_bib0015","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/cancers14071696","article-title":"Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC","volume":"14","author":"Rosar","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111030_bib0016","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111030_bib0017","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"issue":"0","key":"10.1016\/j.urolonc.2026.111030_bib0018","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"0","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.111030_bib0019","article-title":"AlphaBet: combination of Radium-223 and [17 7Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)","volume":"9","author":"Kostos","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111030_bib0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111030_bib0021","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.2967\/jnumed.122.264953","article-title":"Prediction of response to 177Lu-PSMA therapy based on tumor-to-kidney ratio on pretherapeutic PSMA PET\/CT and posttherapeutic tumor-dose evaluation in mCRPC","volume":"64","author":"Hohberg","year":"2023","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111030_bib0022","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.123.265448","article-title":"Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy","volume":"65","author":"Herrmann","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111030_bib0023","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"Delker","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2026.111030_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.06.3869","article-title":"177Lu-PSMA-617 single-photon emission computed tomography\/computed tomography dosimetry and radiobiological models demonstrate decreasing tumor-to-kidney dose ratio with successive cycles","author":"Fitzpatrick","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"10.1016\/j.urolonc.2026.111030_bib0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2967\/jnumed.121.262245","article-title":"Kidney doses in 177Lu-based radioligand therapy in prostate cancer: is dose estimation based on reduced dosimetry measurements feasible?","volume":"63","author":"Mix","year":"2022","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111030_bib0026","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111030_bib0027","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111030_bib0028","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/diagnostics11030428","article-title":"Correlation of an index-lesion-based SPECT dosimetry method with mean tumor dose and clinical outcome after 177Lu-PSMA-617 radioligand therapy","volume":"11","author":"V\u00f6lter","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111030_bib0029","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00259-023-06326-w","article-title":"Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"50","author":"Cytawa","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111030_bib0030","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111030_bib0031","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111030_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"41","author":"Tagawa","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111030_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5127","article-title":"PSMA-delay castration (DC): an open-label, multicenter, randomized phase 3 study of [177 Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC)","volume":"43","author":"Sartor","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111030_bib0034","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111030_bib0035","unstructured":"Study Details https:\/\/clinicaltrials.gov\/study\/NCT06574880; 2025. Accessed August 7, 2025"},{"issue":"36","key":"10.1016\/j.urolonc.2026.111030_bib0036","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1200\/JCO-25-01553","article-title":"177Lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): An open-label, randomized, controlled, phase II study","volume":"43","author":"Kishan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.urolonc.2026.111030_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS256","article-title":"ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug","volume":"42","author":"Hawkins","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111030_bib0038","article-title":"Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","volume":"14","author":"Hansen","year":"2024","journal-title":"Front Oncol"},{"issue":"4_suppl","key":"10.1016\/j.urolonc.2026.111030_bib0039","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS251","article-title":"CaboLu: a phase 1b study of cabozantinib (cabo) in combination with lutetium (Lu 177) vipivotide tetraxetan (LVT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Galarza Fortuna","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111030_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: Phase 1 trial of 177Lu-PSMA-617 and Olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111030_bib0041","unstructured":"Study Details. Accessed August 19, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05113537?cond=%22Castration-Resistant%20Prostate% 20Carcinoma%22&intr=%22chelating%20agents%22&viewType= Table&rank=3"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111030_bib0042","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5016","article-title":"177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)","volume":"43","author":"Sandhu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111030_bib0043","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/pros.24857","article-title":"The safety and efficacy of targeted alpha therapy, ac-225 prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"85","author":"Besiroglu","year":"2025","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111030_bib0044","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2967\/jnumed.119.229393","article-title":"Preclinical evaluation of 203\/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer","volume":"61","author":"Banerjee","year":"2020","journal-title":"J Nucl Med"},{"issue":"Suppl 3","key":"10.1016\/j.urolonc.2026.111030_bib0045","doi-asserted-by":"crossref","first-page":"90S","DOI":"10.2967\/jnumed.115.170175","article-title":"Prostate-specific membrane antigen-targeted radiohalogenated PET and therapeutic agents for prostate cancer","volume":"57","author":"Rowe","year":"2016","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111030_bib0046","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.semnuclmed.2025.09.005","article-title":"Development of PSMA-targeted alpha therapy using [211At]PSMA-5","volume":"55","author":"Watabe","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111030_bib0047","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.7150\/thno.38882","article-title":"Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer","volume":"10","author":"Shen","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111030_bib0048","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111030_bib0049","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111030_bib0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","article-title":"Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT","volume":"46","author":"Rathke","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2026.111030_bib0051","article-title":"Effective treatment of human prostate carcinoma xenografts with single-dose PSMA-targeted [211At]YF2","author":"Feng","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111030_bib0052","doi-asserted-by":"crossref","first-page":"818","DOI":"10.21037\/atm-20-6446","article-title":"Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET\/CT and clinical parameters","volume":"9","author":"Moazemi","year":"2021","journal-title":"Ann Transl Med"},{"issue":"10477","key":"10.1016\/j.urolonc.2026.111030_bib0053","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(25)00202-8","article-title":"The rise of agentic AI teammates in medicine","volume":"405","author":"Zou","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111030_bib0054","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111030_bib0055","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111030_bib0056","first-page":"995","article-title":"Treatment response evaluation in prostate cancer using PSMA PET\/CT","volume":"66","author":"Gafita","year":"2025","journal-title":"J Nucl Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:20:52Z","timestamp":1789759252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926000414"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111030","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of radiopharmaceutical therapy in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}